BML Capital Management
Latest statistics and disclosures from BML Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACRS, SGOV, AVIR, ADVM, ANTX, and represent 65.50% of BML Capital Management's stock portfolio.
- Added to shares of these 10 stocks: EPIX (+$7.6M), IKNA, AVIR, PMVP, ATHA, TIL, ORMP, Palvella Therapeutics Inc Ne, KZR, AADI.
- Started 4 new stock positions in EPIX, KZR, ATHA, Palvella Therapeutics Inc Ne.
- Reduced shares in these 10 stocks: BIL (-$16M), TECX (-$6.4M), RPHM (-$5.9M), LENZ, VNDA, SGOV, Pieris Pharmaceuticals, CALC, TLIS, FBRX.
- Sold out of its positions in FBRX, CALC, Pieris Pharmaceuticals, RPHM, BIL, TLIS, TECX, VNDA.
- BML Capital Management was a net seller of stock by $-11M.
- BML Capital Management has $161M in assets under management (AUM), dropping by -5.29%.
- Central Index Key (CIK): 0001616824
Tip: Access up to 7 years of quarterly data
Positions held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BML Capital Management
BML Capital Management holds 25 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics (ACRS) | 22.0 | $35M | 14M | 2.48 |
|
|
| Ishares Tr 0-3 Mnth Treasry (SGOV) | 16.2 | $26M | -3% | 260k | 100.32 |
|
| Atea Pharmaceuticals (AVIR) | 15.8 | $26M | +14% | 7.6M | 3.35 |
|
| Adverum Biotechnologies Com New (ADVM) | 6.6 | $11M | 2.3M | 4.67 |
|
|
| An2 Therapeutics (ANTX) | 4.9 | $7.9M | 5.7M | 1.38 |
|
|
| Instil Bio Com New (TIL) | 4.7 | $7.6M | +19% | 400k | 19.09 |
|
| Essa Pharma Com New (EPIX) | 4.7 | $7.6M | NEW | 4.2M | 1.79 |
|
| Aadi Bioscience (AADI) | 4.1 | $6.6M | +5% | 2.1M | 3.15 |
|
| Oramed Pharmaceuticals Com New (ORMP) | 4.0 | $6.4M | +20% | 2.6M | 2.42 |
|
| Ikena Oncology (IKNA) | 3.7 | $5.9M | +395% | 3.6M | 1.64 |
|
| Pmv Pharmaceuticals (PMVP) | 3.3 | $5.2M | +105% | 3.5M | 1.51 |
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 2.9 | $4.7M | 4.1M | 1.14 |
|
|
| Connect Biopharma Hldgs Ads (CNTB) | 1.8 | $2.9M | 2.1M | 1.38 |
|
|
| Milestone Pharmaceuticals (MIST) | 1.7 | $2.7M | 1.1M | 2.36 |
|
|
| Athira Pharma (ATHA) | 1.0 | $1.6M | NEW | 2.8M | 0.59 |
|
| Astrotech Corp (ASTC) | 0.9 | $1.5M | 220k | 6.72 |
|
|
| Lisata Therapeutics (LSTA) | 0.5 | $848k | 285k | 2.98 |
|
|
| Palvella Therapeutics Inc Ne | 0.3 | $506k | NEW | 42k | 12.00 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $443k | 150k | 2.95 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.2 | $327k | NEW | 49k | 6.72 |
|
| Lenz Therapeutics (LENZ) | 0.2 | $268k | -84% | 9.3k | 28.87 |
|
| Nextcure (NXTC) | 0.1 | $211k | 274k | 0.77 |
|
|
| Verrica Pharmaceuticals (VRCA) | 0.1 | $122k | -2% | 175k | 0.70 |
|
| Allovir (ALVR) | 0.0 | $77k | -69% | 184k | 0.42 |
|
| Hillevax (HLVX) | 0.0 | $43k | +5% | 21k | 2.07 |
|
Past Filings by BML Capital Management
SEC 13F filings are viewable for BML Capital Management going back to 2022
- BML Capital Management 2024 Q4 filed Feb. 7, 2025
- BML Capital Management 2024 Q3 filed Nov. 5, 2024
- BML Capital Management 2024 Q2 filed Aug. 7, 2024
- BML Capital Management 2024 Q1 restated filed April 24, 2024
- BML Capital Management 2024 Q1 filed April 23, 2024
- BML Capital Management 2023 Q4 restated filed Feb. 2, 2024
- BML Capital Management 2023 Q4 filed Jan. 30, 2024
- BML Capital Management 2023 Q3 filed Oct. 23, 2023
- BML Capital Management 2023 Q2 filed July 24, 2023
- BML Capital Management 2023 Q1 filed April 14, 2023
- BML Capital Management 2022 Q4 filed Feb. 13, 2023